ASH 2024: Wael Gamal, PhD on PI3K Inhibition to Enhance CAR T-Cell Therapy in CLL

Challenges in the clinical implementation of the CAR T-cell therapy A2B694Подробнее

Hot topics in CAR T-cell therapy for ALLПодробнее

The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALLПодробнее

Manufacturing strategies to improve CAR T-cell persistenceПодробнее

Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cellsПодробнее

Advancements and challenges in CAR-T cell therapyПодробнее

Developing an AvidCAR platform to improve T-cell activityПодробнее

Strategies to improve CAR T-cell manufacturingПодробнее

Integration of CAR T-cell therapy: working with industryПодробнее

Developing the next generation of CAR-T cellsПодробнее

Scaling up CAR-T manufacturing with automation and digitalizationПодробнее

Optimizing CAR-T therapy in LBCLПодробнее

CAR-T cell therapy: current applications and how to improve treatment strategies in the futureПодробнее

The benefits of CAR-T therapy in 2L over 3L in R/R DLBCLПодробнее